Back to Trials
NCT04119102PHASE4Recruiting

Duobrii in Combination With Biologics

Psoriasis Treatment Center of Central New Jersey

Start Date

10/14/2019

Completion Date

9/1/2020

Summary

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Detailed Description

A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures Exclusion Criteria: 1. Psoriasis affecting ˂2% or \>10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII

Interventions

DRUG

Duobrii

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Psoriasis

Locations

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey 08520

United States